RecruitingNCT02931513

sCD163 in PBC Patients - Assessment of Treatment Response

Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCA

Sponsor

University of Aarhus

Enrollment

40 participants

Start Date

Sep 1, 2016

Study Type

OBSERVATIONAL

Conditions

Primary Biliary Cirrhosis Liver Inflammation Ursodeoxycholic Acid

Summary

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blood samples, a medical device called Fibroscan, and others for people with liver inflammation, primary biliary cirrhosis, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.